Emulsifying Solution Prepared by an AI-based Drug Delivery System (AIDDS™) Enhances Bioavailability of Silymarin

Hong, Junkee; Jeon, Byung-Ju; Myeong, Jaeho; Kim, Ga‐Young; Lee, Jiwon; Kim, Sung‐Su

doi:10.52361/fsbh.2021.1.e23

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, proper selection of formulation techniques and compositional materials in designing therapeutic delivery systems plays a crucial role in producing a marketable, safe, and functional product [ 43 ]. Lipid-based carriers such as solid lipid nanoparticles (SLNs) [ 44 , 45 ], micro/nanoemulsions [ 46 , 47 ], and liposomes [ 48 , 49 , 50 ] are among the key examples of successful carriers in solubilizing flavonoids and flavonolignans in aqueous environments. This study seeks to assess recent developments in formulation tactics which have made flavonoids and flavonolignans more biologically available.…”

Section: Introductionmentioning

confidence: 99%

Lipid-Based Delivery Systems for Flavonoids and Flavonolignans: Liposomes, Nanoemulsions, and Solid Lipid Nanoparticles

et al. 2023

View full text Add to dashboard Cite

Herbal chemicals with a long history in medicine have attracted a lot of attention. Flavonolignans and flavonoids are considered as two classes of the above-mentioned compounds with different functional groups which exhibit several therapeutic capabilities such as antimicrobial, anti-inflammatory, antioxidant, antidiabetic, and anticancer activities. Based on the studies, high hydrophobic properties of the aforementioned compounds limit their bioavailability inside the human body and restrict their wide application. Nanoscale formulations such as solid lipid nanoparticles, liposomes, and other types of lipid-based delivery systems have been introduced to overcome the above-mentioned challenges. This approach allows the aforementioned hydrophobic therapeutic compounds to be encapsulated between hydrophobic structures, resulting in improving their bioavailability. The above-mentioned enhanced delivery system improves delivery to the targeted sites and reduces the daily required dosage. Lowering the required daily dose improves the performance of the drug by diminishing its side effects on non-targeted tissues. The present study aims to highlight the recent improvements in implementing lipid-based nanocarriers to deliver flavonolignans and flavonoids.

show abstract